Michael Raab Sells 10,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Michael Raab sold 10,000 shares of the company’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $142,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up 2.38% during mid-day trading on Friday, hitting $13.77. 885,178 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $14.35 and its 200-day moving average price is $11.26. Amicus Therapeutics, Inc. has a one year low of $4.41 and a one year high of $16.60. The stock’s market cap is $2.27 billion.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. During the same quarter in the previous year, the business earned ($0.40) earnings per share. On average, analysts forecast that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/michael-raab-sells-10000-shares-of-amicus-therapeutics-inc-fold-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of FOLD. FMR LLC raised its stake in shares of Amicus Therapeutics by 3.4% during the second quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock worth $215,876,000 after purchasing an additional 705,153 shares during the last quarter. Redmile Group LLC raised its stake in shares of Amicus Therapeutics by 5.9% during the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock worth $121,282,000 after purchasing an additional 668,080 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Amicus Therapeutics by 5.0% during the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after purchasing an additional 430,486 shares during the last quarter. Palo Alto Investors LLC raised its stake in shares of Amicus Therapeutics by 0.7% during the second quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock worth $79,964,000 after purchasing an additional 57,800 shares during the last quarter. Finally, Janus Capital Management LLC raised its stake in shares of Amicus Therapeutics by 3.6% during the first quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock worth $50,883,000 after purchasing an additional 244,906 shares during the last quarter.

A number of research analysts have recently commented on FOLD shares. Cowen and Company restated a “buy” rating and issued a $16.00 price target (up from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Chardan Capital upped their price target on shares of Amicus Therapeutics from $12.50 to $17.50 and gave the stock a “buy” rating in a report on Thursday, August 10th. BidaskClub cut shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 2nd. Bank of America Corporation increased their target price on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 4th. Finally, Leerink Swann reiterated a “buy” rating and set a $20.00 target price (up from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $17.81.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply